SEC EDGARAUG 191 min read$REPL

Hill Emily Luisa sold $132K of REPL

Hill Emily Luisa (Chief Financial Officer) sold 9,256 shares of Replimune Group, Inc. (REPL) at $14.28 ($0.13M total) on 2026-08-17.

Original reporting

SEC EDGAR · Hill Emily Luisa

Published Aug 19, 2026, 10:42 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 19, 2026, 10:53 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$REPL

Neutral

medium confidence

Mentioned

$REPL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$REPLNeutralLow

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but it adds to the flow of insider activity data.

Market read

A routine insider sale with limited trading relevance; investors may note but unlikely to act.

What to watch

Potential upcoming corporate actions or personal tax planning may have driven the sale.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-08-19

Background

Form 4 filings disclose insider transactions; CFO sales are monitored for potential signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$REPLNeutralMedium confidence

Context

CFO Emily Luisa Hill sold 9,256 shares for $132,176, reducing her stake to 215,852 shares.

Expected impact

Minimal short-term price pressure, likely within normal volatility range.

Evidence & confidence

The transaction size is modest relative to market cap and typical insider activity, so any price effect is expected to be limited.

Market effects

Sector

No immediate sector-wide impact; biotech sector remains driven by broader pipeline news.

Regional

Limited to US markets where REPL trades; no broader regional effect.

Global

Insignificant on a global scale.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move rather than a negative signal.

Key entities

Company
Replimune Group, Inc.
Biotech firm focused on cancer immunotherapy, ticker REPL.
Executive
Emily Luisa Hill
Chief Financial Officer of Replimune Group, Inc.

Read at source ← All news

SEP 11

$MRNAHighAI 9/10

New FDA Drug Approvals - August 2026

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

finanznachrichten.de3 min

SEP 11

$REPLHighAI 8/10

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

stocktwits.com2 min

SEP 4

$REPLMed

Did FDA’s RP1 Rejection and New Lawsuits Just Shift Replimune Group’s (REPL) Risk Narrative?

Replimune Group (REPL) faces securities class action lawsuits following the FDA's rejection of its RP1 Biologics License Application due to study design issues. The company will discuss its outlook at the Cantor Global Healthcare Conference. Analysts note increased regulatory and legal risks, with shares potentially trading above fair value.

simplywall.st2 min

SEP 3

$REPLHighAI 9/10

FDA Leadership Overrules Staff Concerns To Grant Replimune Accelerated Approval For Tudriqev

Replimune (REPL) received FDA accelerated approval for its cancer therapy Tudriqev, despite staff concerns, after senior FDA leadership intervened. The Oncology Center of Excellence played a key role. Accelerated approval requires confirmatory trials. This marks a significant milestone for Replimune in the competitive oncology market.

londoninsider.co.uk2 min

SEP 2

$REPLHighAI 8/10

Replimune Group stock hits 52-week high at 16.2 USD

Replimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.

investing.com2 min

AUG 27

$REPLLowAI 8/10

ReplimuneÂ Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.

tipranks.com2 min